Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
aPDT + doxycycline is a combination therapy that utilizes antimicrobial photodynamic therapy (aPDT) alongside the antibiotic doxycycline. aPDT is a local, painless antimicrobial treatment that involves applying photosensitizing compounds which, when activated by light, generate reactive oxygen species (ROS) that cause oxidative damage to microbial cells. Doxycycline is a tetracycline antibiotic that works by inhibiting bacterial protein synthesis. The combination appears to be particularly effective in treating periodontal disease in patients with type 2 diabetes mellitus, showing improvements in both periodontal clinical parameters and glycemic control (HbA1c levels). Studies suggest that aPDT may serve as an alternative to systemic antibiotics when used in conjunction with scaling and root planing (SRP), potentially reducing concerns about antibiotic resistance.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on aPDT + doxycycline.